Rat B1 Bradykinin Receptor (BDKRB1) ELISA Kit

Product specifications

ELISA Kits

B1 Bradykinin Receptor (BDKRB1)

Rat

Colorimetric

Quantitative

Sandwich

0.156 ng/ml - 10 ng/ml

Optimal dilutions/concentrations should be determined by the end user.

96 tests

Lyophilized

ELISA

Tissue homogenates, cell lysates and other biological fluids.

Shipped within 5-15 working days. The validity for this kit is 6 months.

Shipped at 4 °C. Upon receipt, store the kit according to the storage instruction in the kit's manual.

No

P97583

BDKRB1,B1BKR,BKR1,B1R,bradykinin receptor,BKB1R,BRADYB1

Elisa kits for BDKRB1

RUO

Validity: The validity for this kit is 6 months.
This product is for research use only.   The range and sensitivity is subject to change. Please contact us for the latest product information. For accurate results, sample concentrations must be diluted to mid-range of the kit. If you require a specific range, please contact us in advance or write your request in your order comments.   Please note that our ELISA and CLIA kits are optimised for detection of native samples, rather than recombinant proteins. We are unable to guarantee detection of recombinant proteins, as they may have different sequences or tertiary structures to the native protein.

Descripción

Bradykinin Receptor B1 (BDKRB1) is an inducible GPCR primarily expressed during inflammatory responses and tissue injury. Unlike the constitutively expressed B2 receptor, B1 is induced by pro-inflammatory cytokines, such as IL-1β and TNF-α, in response to chronic inflammation, trauma, or infection. BDKRB1 binds des-Arg9-bradykinin, a bradykinin metabolite, and mediates pro-inflammatory effects, including pain sensitization, vasodilation, and vascular permeability. This receptor plays a pivotal role in chronic pain conditions, such as neuropathic pain and inflammatory hyperalgesia, by sensitizing sensory neurons and enhancing pain signaling. BDKRB1 also contributes to angiogenesis and leukocyte recruitment, facilitating immune responses during infection and injury. In the cardiovascular system, B1 activation is associated with hypertension, vascular remodeling, and endothelial dysfunction. Dysregulation of BDKRB1 signaling is linked to conditions like diabetic complications, chronic inflammatory diseases, and certain cancers, where it can promote tumor growth and metastasis. Targeting BDKRB1 with antagonists has shown promise in preclinical models for managing chronic pain, inflammation, and vascular disorders, making it an emerging target for therapeutic development.

Related Products

B1 Bradykinin Receptor (BDKRB1) Antibody

Bradykinin, a 9 aa peptide, is generated in pathophysiologic conditions such as inflammation, trauma, burns, shock, and allergy. Two types of G-protein coupled receptors have been found which bind bradykinin and mediate responses to these pathophysiologic conditions. BDKRB1 is one of these receptors and is synthesized de novo following tissue injury. Receptor binding leads to an increase in the cytosolic calcium ion concentration, ultimately resulting in chronic and acute inflammatory responses.

Ver Producto

Bradykinin Receptor B1 (BDKRB1) Antibody

BDKRB1 Antibody is a Rabbit Polyclonal against BDKRB1.

Ver Producto

Bradykinin Receptor B1 (BDKRB1) Antibody

Bradykinin receptor B1 Antibody is a Goat Polyclonal antibody against Bradykinin receptor B1.

Ver Producto